New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For AAPL;JPM;RDSA;NVS;BKS;WDC;GD;VIA;VIAB;BLK;MPC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | all recent news | >>
February 24, 2015
09:06 EDTJPMJPMorgan CFO says company seeks to raise dividends if approved
Subscribe for More Information
09:01 EDTJPMJPMorgan expects legal costs to ease, but remain above pre-crisis levels
08:55 EDTJPMJPMorgan expect net charge offs to remain low at $4B+ in 2015
Subscribe for More Information
08:39 EDTAAPLApple near-term capital return could be less than expected, says UBS
UBS said they believe Apple could take a near-term breather on capital returns due to potential U.S. tax reform, increased dependence on debt issuance for stock buyback funding, and the potential for its board to wait for more clarity on repatriation. UBS reiterated its Buy rating and $150 price target on Apple shares.
07:21 EDTVIA Viacom reportedly planning job cuts, Bloomberg says
Subscribe for More Information
07:21 EDTJPMSecurities Industry & Financial Markets Association to hold a conference
Subscribe for More Information
06:39 EDTAAPLVisa Europe announces 'tokenisation service'
Subscribe for More Information
06:29 EDTAAPLApple hiring chip, battery experts from Samsung, Korea Times reports
Subscribe for More Information
06:27 EDTAAPLApple said to buy music plug-in and effect makker Camel Audio, MacRumors says
Subscribe for More Information
06:15 EDTJPMBanks probed for possible rigging of precious metals markets, WSJ reports
Officials in the U.S. are investigating at least 10 major banks for potential rigging of precious-metals markets, sources tell The Wall Street Journal. The DOJ's antitrust unit are investigating the price-setting process for gold, silver, palladium and platinum in London, while the CFTC has begun a civil investigation, with both agencies making requests for information, including a subpoena to HSBC (HSBC) from the CFTC. According to a source, Credit Suisse (CS), JP Morgan (JPM), UBS (UBS), Societe Generale (SCGLY), Bank of Nova Scotia (BNS), Barclays (BCS), Goldman Sachs (GS) and Deutsche Bank (DB) are also under investigation. Reference Link
06:12 EDTJPMJPMorgan plans to charge fees for deposits from large clients, WSJ says
JPMorgan is planning to charge corporate clients, hedge funds, private-equity firms, and foreign banks for deposits due to regulatory rules that impose costs on holding money viewed as "prone to fleeing" during financial stress, reports the Wall Street Journal, citing an internal memo and people familiar with the plan. Clients will be asked to pay a fee or move funds to other products such as money-fund sweep accounts. Retail customers are unaffected. Reference Link
06:06 EDTAAPLApple's market cap hits nearly $775B, CNBC reports
Apple's (AAPL) market cap has reached nearly $775B after the stock closed at a record on Monday, up over 2.7% to $133, CNBC reports. Exxon Mobil (XOM) has a market cap of about $377B. Reference Link
05:59 EDTAAPLStocks with implied volatility movement; BBRY AAPL
Subscribe for More Information
February 23, 2015
16:00 EDTAAPLOptions Update; February 23, 2015
Subscribe for More Information
15:17 EDTAAPLAOL iTunes login pact with Apple ending soon, AppleInsider says
Subscribe for More Information
15:00 EDTNVSFDA approves Farydak for treatment of multiple myeloma
The FDA approved Farydak for the treatment of patients with multiple myeloma, a form of blood cancer that arises from plasma cells, a type of white blood cell, found in bone marrow. Farydak is the first HDAC inhibitor approved to treat multiple myeloma. It is intended for patients who have received at least two prior standard therapies, including bortezomib and an immunomodulatory agent. Farydak is to be used in combination with bortezomib, a type of chemotherapy, and dexamethasone, an anti-inflammatory medication. Farydak is marketed by Novartis.
13:40 EDTNVSAnalysts clash on Spectrum outlook after patent suit setback
Two research firms had divergent views on Spectrum Pharmaceuticals (SPPI) after a judge ruled that a drug which could compete with the company's Fusilev treatment does not infringe on the company's intellectual property. BACKGROUND: Late Friday, a federal judge ruled that Novartis' (NVS) levoleucovorin, a generic version of Spectrum's Fusilev, does not infringe on Spectrum's intellectual property. Fusilev is indicated after high-dose methotrexate therapy in osteosarcoma, a type of cancer that starts in the bones. It is also used to treat patients with advanced metastatic colorectal cancer. BEARISH TAKE: Roth Capital analyst Joseph Pantginis downgraded Spectrum to Neutral from Buy following the ruling, as he believes the risk to the company's revenue has risen. The company is meaningfully less likely to become profitable again, wrote Pantginis, noting that Fusilev accounted for about 50% of the company's product revenue. According to the analyst, Spectrum is becoming increasingly focused on developing its earlier stage drugs, and he expects those drugs to grow slowly. Pantginis slashed his price target on the shares to $7 from $15. BULLISH TAKE: In a note to investors earlier today, Reni Benjamin, an analyst at research firm H.C. Wainwright, wrote that the stock's plunge after the judge's ruling "creates a table-pounding buying opportunity," noting that Fusilev has been granted exclusivity as a colorectal treatment until 2018. Benjamin does not expect the company's revenue from Fusilev to decline at all until 2018, as a citizen's petition submitted by Spectrum to the FDA, along with an appeal the company is mounting to Friday's ruling, and the difficulty that Novartis will have launching its version of the drug while the appeal is ongoing, will help prevent Spectrum's revenue from dropping. Also likely to protect Spectrum's revenue are the strong relationships that the company has developed with hospitals and community doctors, the analyst stated. He kept a $15 price target and Buy rating on the shares. PRICE ACTION: In mid-afternoon trading, Spectrum tumbled $1.44, or 19.3% to $6.02.
12:28 EDTAAPLGoogle reaches deal with wireless carriers, acquires Softcard tech, Re/code says
Subscribe for More Information
12:21 EDTNVS, AAPLOn The Fly: Midday Wrap
Subscribe for More Information
12:12 EDTAAPLReport: Apple may be targeting next-gen experts from Samsung, Apple Insider says
Subscribe for More Information
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use